| |
|
|
|
|
|
|
|||
|
Blood, Vol. 92 No. 10 (November 15), 1998:
pp. 3756-3771
From the Department of Rheumatology, Hospital for Joint Diseases, New
York, NY; the Department of Pathology, Kaplan Comprehensive Cancer
Center, New York University School of Medicine, New York, NY; and the
Laboratory of Immunology, National Institutes of Health, Bethesda, MD.
The influence of ligand:receptor affinity on B-cell antigen receptor
(BCR)-induced apoptosis in the IgM+ Burkitt lymphoma
line, Ramos, was evaluated with a group of affinity-diverse murine
monoclonal antibodies (MoAbs) specific for human B-cell IgM. The
studies showed not only a minimal affinity threshold for the induction
of apoptosis, but, interestingly, also a maximal affinity threshold
above which increases in affinity were associated with diminished
apoptosis. The lesser capacity of high-affinity MoAb to induce
apoptosis was paralleled by a lesser capacity to induce receptor
cross-linking. At high ligand concentration, high MoAb affinity was
also associated with a diminished capacity to induce early protein
tyrosine phosphorylation. The compromised capacity of two high-affinity
MoAbs to trigger apoptosis may be, at least in part, explained by two
separate phenomena that can impair the formation of mIgM cross-links:
(1) more stable univalent binding and (2) a tendency for monogamous
binding of both MoAb Fab to two Fab epitopes on mIgM. These in vitro
studies suggest that the use of the highest affinity MoAbs for
antireceptor immunotherapies that depend on receptor cross-linking
might, on occasion, be contraindicated.
This article has been cited by other articles:
| |||||||||||
| Copyright © 1998 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||